First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Ionis Pharmaceuticals, Inc.

    IONS · 14 developments mapped · last assessed 2026-09-25

    Market Ontology has mapped 14 macro, policy, and market developments to Ionis Pharmaceuticals, Inc. since 2026-08-26. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for IONS yet, so no modelled value is shown. The IONS valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run IONS on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for IONS. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease

      Direct clinical trial success leading to potential regulatory submission and future commercialization. Increased probability of milestone payments and royalty streams.

      · Moves probability of success for pipeline assets, peak sales estimates for ulefnersen and sefaxersen, discount rate (due to reduced risk)

    • Main threat

      Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen

      Direct impact from clinical trial failures, reducing future revenue potential and increasing R&D risk perception.

      · Moves probability of success for pipeline assets, peak sales estimates for pelacarsen and eplontersen, discount rate reflecting increased risk

    • Open question

      Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms

      Increased investor attention on neurodegenerative drug development, potential for partnership or competitive landscape shifts.

      · Moves probability of success pipeline, peak sales estimates

    What changed, by assumption

    Probability of success for pipeline assets
    • 2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease
    • 2026-09-24Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease
    • 2026-09-24Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy Therapies
    • 2026-09-24Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs
    Acquisition premium
    • 2026-09-23Roche to Acquire Ionis Pharmaceuticals, Inc.
    Probability of success for pelacarsen and eplontersen
    • 2026-09-21Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacks
    Market share for spinraza (nusinersen)
    • 2026-09-12FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy
    Investor perception of pipeline risk
    • 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-09-23RevenueBullishPositive Phase 3 interim data triggers eligibility for regulatory and sales milestone payments and future royalties from partner Roche.0.85
    2026-09-07RevenueBearishPhase 3 Lp(a)HORIZON study for pelacarsen did not meet primary endpoint, likely impacting future royalty and milestone revenue expectations from partner Novartis.0.95
    2026-09-07Valuation multipleBullishTarget re-rates to bid premium until close.0.70
    2026-09-07RevenueBearishPhase 3 Lp(a)HORIZON study for pelacarsen did not meet its primary endpoint, likely impacting future royalty and milestone revenue expectations from partner Novartis.0.95

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-25ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per sharemixed3-12m0.20
    2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseaseBullish1-3m0.90
    2026-09-24Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney diseaseBullish1-3m0.90
    2026-09-24Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy TherapiesBullish1-3m0.90
    2026-09-24Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN ProgramsBullish1-3m0.90
    2026-09-23Roche to Acquire Ionis Pharmaceuticals, Inc.Bullish1-5d0.90
    2026-09-21Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and EplontersenBearish1-3m0.90
    2026-09-21Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish TargetsBearish1-3m0.90
    2026-09-21Ionis slides over 40% year-to-date following late-stage clinical setbacksBearish1-3m0.90
    2026-09-21Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacksBearish3-12m0.90
    2026-09-21Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacksBearish1-3m0.90
    2026-09-12FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapyBearish1-3m0.60